Thursday, Vertex Pharmaceuticals Inc. (VRTX) announced that the FDA has cleared the Investigational New Drug Application or IND for VX-407 for the treatment of autosomal dominant polycystic kidney disease or ADPKD.
VX-407 is a small molecule corrector that targets the root cause of ADPKD, a genetic kidney disease that shortens life expectancy.
ADPKD affects patients with specific PKD1 genetic variations and is characterized by the development of multiple kidney-enlarging cysts. These cysts impair kidney function and can eventually result in kidney failure, necessitating dialysis or a kidney transplant, and causing premature death.
The company is also planning to initiate a Phase 1 clinical trial in healthy volunteers this month.
For comments and feedback contact: editorial@rttnews.com
Business News
December 12, 2025 15:14 ET Central bank decisions dominated the economic news flow this week led by the Federal Reserve. Trade data from the U.S. also gained attention. The Canadian and Swiss central banks also announced their interest rate decisions. Inflation data from China was in focus as the country released the latest consumer price and producer price data.